Biolase Analyst Ratings
BenzingaApr 1 05:38 ET
Biolase's Strong Q4 Performance and Positive 2024 Outlook Affirm Buy Rating
TipRanksMar 23 07:35 ET
Biolase Analyst Ratings
BenzingaMar 22 13:37 ET
Maxim Group Reaffirms Their Buy Rating on Biolase (BIOL)
TipRanksFeb 22 16:05 ET
Positive Clinical Trial Results and Successful Cost Optimization Initiatives Bolster Buy Rating for Biolase Despite Lowered Price Target
TipRanksNov 14, 2023 13:15 ET
Positive McGuire Study Results Boost Biolase's Market Potential and Justify Buy Rating
TipRanksNov 9, 2023 13:46 ET
Maxim Group Sticks to Their Buy Rating for Biolase (BIOL)
TipRanksJun 7, 2023 07:45 ET
Lake Street Adjusts Price Target on Biolase to $0.40 From $1.50, Maintains Buy Rating
MT NewswiresMay 31, 2023 09:51 ET
Lake Street Maintains Buy on Biolase, Lowers Price Target to $0.4
BenzingaMay 31, 2023 09:28 ET
Maxim Group Maintains Buy on Biolase, Lowers Price Target to $1
BenzingaMar 29, 2023 13:01 ET
Lake Street Remains a Buy on Biolase (BIOL)
TipRanksMar 29, 2023 09:36 ET
Benchmark Reiterates Speculative Buy on Biolase, Maintains $2 Price Target
BenzingaMar 29, 2023 07:58 ET
Lake Street Assumes Biolase at Buy, Announces Price Target of $1.5
Benzinga Real-time NewsJan 20, 2023 08:58 ET
Biolase Analyst Ratings
Benzinga Analyst RatingsJan 20, 2023 08:57 ET
Maxim Group Sticks to Their Buy Rating for Biolase (BIOL)
TipRanksJan 19, 2023 14:50 ET
Maxim Group Remains a Buy on Biolase (BIOL)
TipRanksAug 13, 2022 08:35 ET
No Data
No Data